Swain, Sandra M. http://orcid.org/0000-0002-1320-3830
Shastry, Mythili http://orcid.org/0000-0003-2445-8094
Hamilton, Erika http://orcid.org/0000-0002-1911-0336
Article History
Accepted: 21 September 2022
First Online: 7 November 2022
Competing interests
: M.S. reports no conflict of interest. E.H.’s institution has received research funding from the following: AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, AtlasMedx, Bliss BioPharmaceuticals, Cascadian Therapeutics, Clovis, Compugen, Cullen-Florentine, Curis, Dana Farber Cancer Institute, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InventisBio, Jacobio, Karyopharm, Leap Therapeutics, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Merus, Millennium, Molecular Templates, Myraid Genetic Laboratories, Nucana, Olema, OncoMed, Onconova Therapeutics, ORIC Pharmaceuticals, Orinove, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Radius Health, Regeneron, Repertoire Immune Medicine, Rgenix, Sermonix Pharmaceuticals, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Vincerx Pharma, Zenith Epigenetics and Zymeworks. E.H.’s institution has received consulting fees from the following: Arcus, Eisai, Greenwich Lifesciences, H3 Biomedicine, iTeos, Janssen, Loxo, Orum Therapeutics, Propella Therapeutics and Puma Biotechnology; and her institution has received research funding and consulting fees from the following: Arvinas, Black Diamond, Boehringer Ingelheim, CytomX, Dantari, Deciphera, Lilly, Merck, Mersana, Novartis, Pfizer, Relay Therapeutics, Roche/Genentech, SeaGen, Silverback. S.M.S. reports grants or contracts from Genentech/Roche, Kailos, Genetics, BCRF; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Genentech/Roche, Daiichi Sankyo; support for attending meetings and/or travel from Genentech/Roche (travel 11/2019), Daiichi Sankyo (travel 9/2022) and Sanofi (travel 9/2022); participation on a Data Safety Monitoring Board for AstraZeneca; participation in an advisory board for AstraZeneca, Daiichi Sankyo, Exact Sciences, Biotheranostics, Natera, Merck, Silverback Therapeutics, Athenex, Lilly, Aventis; and participation in a Scientific Advisory Board for Inivata. S.M.S. reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: NSABP Vice Chairman; CCF, ASCO Director; and third party writing support from Genentech/Roche and AstraZeneca.
Free to read: This content has been made available to all.